StreetAlpha.app
Home › Stocks › NERV

Minerva Neurosciences, Inc. (NERV)

$2.00
▼ −5.66%
LAST CLOSE · NOV 20

Minerva Neurosciences is a Burlington, Massachusetts drug developer working on roluperidone, a candidate for schizophrenia. It last closed at $2.00 on Nov 20, down 5.66% on the day. The next earnings report for NERV is expected around Wed, Mar 10, 2027. For the quarter ended Sep 2026, NERV reported EPS of -$0.19. Over its last 4 reports the stock moved an average of 4.6% the session after earnings.

AI Auto Pilots
Is NERV in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NERV.

Key Stats

Last 12 months
Results
Net income
−$290.9M
Valuation
Market cap
$99.7M
49.8M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$20.2M
At Sep 30
Shareholder equity
−$97.5M
Shares outstanding
49.8M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$49.9M−$49.9MFY2021FY2022: −$32.1M−$32.1MFY2022FY2023: −$30.0M−$30.0MFY2023FY2024: $1.4M$1.4MFY2024FY2025: −$293.4M−$293.4MFY2025

From NERV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
Mar 10
Estimated date · Time not announced
Reported EPS
-$0.19
Quarter ended Sep 2026
Year ago EPS
-$0.36
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.56Dec '24Mar 2025: -$0.50Mar '25Jun 2025: -$0.43Jun '25Sep 2025: -$0.36Sep '25Dec 2025: -$33.38Dec '25Mar 2026: -$2.86Mar '26Jun 2026: -$0.14Jun '26Sep 2026: -$0.19Sep '26Latest -$0.19
Revenue by quarter
Not enough quarters on file yet.
How NERV moved after its last 4 reports
Average move the session after a report ±4.6%
Nov 6, 2026Time not announced+5.2%
Aug 7, 2026Time not announced−3.8%
May 5, 2026Time not announced−1.3%
Mar 11, 2026Time not announced−8.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NERVStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NERV
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NERV

Technical Analysis

NERV · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 16% below its 20 day and 40% below its 50 day average. It is 138% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the 52 week low at $1.96, and the nearest resistance the Pivot at $2.04.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 11.8%/day
Key levels
$8.8052 week high+340.0%
$4.75200 day average+137.5%
$3.63100 day average+81.5%
$2.8050 day average+40.0%
$2.65Swing high (Oct 23)+32.5%
$2.3120 day average+15.5%
$2.09Pivot R1+4.5%
$2.04Pivot+2.0%
$2.00Last close
$1.9652 week low−2.0%
$1.96Swing low (Oct 30)−2.0%
$1.95Pivot S1−2.5%
Indicators
RSI (14)33.07Weak, oversold below 30Neutral
MACD-0.18Below its signal lineBearish
Stochastic13.3Near the bottom of its rangeOversold
ADX (14)20.2Weak trend
Williams %R-98.7Oversold below −80, overbought above −20Oversold
CCI (20)-153.2Oversold below −100, overbought above 100Oversold
Rate of change−17.4%Change over 10 sessionsBearish
ATR (14)$0.24Typical daily range, 11.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NERV

What happened before

See how NERV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NERV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NERV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NERVHow many large options trades hit NERV, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NERV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲33 buying vs 11 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6558+12.1%
In funds' top 10110.0%
Held by funds86.6%84.9%+1.7 pts
New / increased9 / 2422 / 15−10.8%
Reduced / sold out9 / 27 / 9−31.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NERV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NERV is in one of them and how their past NERV trades turned out.

NERV in the AI portfolios
Loading…

NERV News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NERV in an article yet. Here's the latest on the wider market.

NERV in the news

About Minerva Neurosciences

Minerva Neurosciences is a pharmaceutical company based in Burlington, Massachusetts. Its main focus is roluperidone, a drug candidate being developed to treat negative symptoms of schizophrenia. The candidate is still moving through clinical trials and the U.S. regulatory approval process, so it is not yet approved for sale. The company's intended customers are patients with schizophrenia, along with the doctors and healthcare providers who treat them.

Headquarters
Burlington, MA
Founded
2007